Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, and other solid tumors. It is also developing immunokinase inhibitors comprising DCC-3014 that is in Phase I trial for treatment of solid tumors and hematologic malignancies; and Rebastinib, which is in Phase 1b trial to treat breast cancer, as well as to investigate in combination with chemotherapy and checkpoint inhibitors. The company was founded in 2003 and is headquartered in Waltham, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone781-209-6400
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable
Deciphera Pharmaceuticals (NASDAQ:DCPH) Frequently Asked Questions
What is Deciphera Pharmaceuticals' stock symbol?
Deciphera Pharmaceuticals trades on the NASDAQ under the ticker symbol "DCPH."
How were Deciphera Pharmaceuticals' earnings last quarter?
Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) released its earnings results on Thursday, March, 14th. The company reported ($0.86) earnings per share for the quarter, missing the consensus estimate of ($0.73) by $0.13. View Deciphera Pharmaceuticals' Earnings History.
When is Deciphera Pharmaceuticals' next earnings date?
What price target have analysts set for DCPH?
10 equities research analysts have issued 1-year price targets for Deciphera Pharmaceuticals' shares. Their predictions range from $20.00 to $65.00. On average, they anticipate Deciphera Pharmaceuticals' stock price to reach $44.00 in the next twelve months. This suggests a possible upside of 85.9% from the stock's current price. View Analyst Price Targets for Deciphera Pharmaceuticals.
What is the consensus analysts' recommendation for Deciphera Pharmaceuticals?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Deciphera Pharmaceuticals in the last year. There are currently 1 sell rating, 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Deciphera Pharmaceuticals.
What are Wall Street analysts saying about Deciphera Pharmaceuticals stock?
Here are some recent quotes from research analysts about Deciphera Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Deciphera Pharmaceuticals, LLC is a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib which are in clinical stage. Deciphera Pharmaceuticals, LLC is based in WALTHAM, United States. " (2/12/2019)
- 2. Cantor Fitzgerald analysts commented, "We are Overweight on DCPH with a 12-month price target of $53 based on lead asset DCC-2618 (in 4L GIST). Compelling safety and clinical activity data were presented at ASCO ‘18, which we view positively when compared to SOC sunitinib in earlier 2L patients. We believe the recent data de-risks the P3 program for 4L pts, reads on the broad potential in GIST & other malignancies, and reinforces our conviction in the platform/clinical strategy. In addition, emerging ‘2618 data in 2L/3L pts suggest superiority to SOC in terms of response rate & durability, a clinical profile that could drive ~$2.7B in peak sales." (12/20/2018)
- 3. Canaccord Genuity analysts commented, "We continue to expect DCC-2618 durability in GIST cohorts will be a key focus for investors. The Phase 1 is assessing DCC-2618 in 3 separate indications, GIST (cohorts for 2L, 4L, and 5L), advanced systemic mastocytosis (aSM), and glioma/ glioblastoma multiforme (GBM). In November, Deciphera initiated pivotal Invictus trial in 4L GIST and plans to start second Ph3 Intrigue 2L GIST trial by year-end. DCC-2618 has US and EU orphan designation." (8/13/2018)
Has Deciphera Pharmaceuticals been receiving favorable news coverage?
News headlines about DCPH stock have trended somewhat positive this week, InfoTrie reports. The research group ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Deciphera Pharmaceuticals earned a daily sentiment score of 1.2 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future.
Who are some of Deciphera Pharmaceuticals' key competitors?
Some companies that are related to Deciphera Pharmaceuticals include ACADIA Pharmaceuticals (ACAD), Ultragenyx Pharmaceutical (RARE), Agios Pharmaceuticals (AGIO), Blueprint Medicines (BPMC), Global Blood Therapeutics (GBT), Amicus Therapeutics (FOLD), Emergent Biosolutions (EBS), Biohaven Pharmaceutical (BHVN), Intercept Pharmaceuticals (ICPT), Ligand Pharmaceuticals (LGND), Akcea Therapeutics (AKCA), Insmed (INSM), Reata Pharmaceuticals (RETA), Portola Pharmaceuticals (PTLA) and Mirati Therapeutics (MRTX).
What other stocks do shareholders of Deciphera Pharmaceuticals own?
Who are Deciphera Pharmaceuticals' key executives?
Deciphera Pharmaceuticals' management team includes the folowing people:
- Dr. Michael D. Taylor, Pres, CEO & Director (Age 64)
- Dr. Daniel L. Flynn, Founder & Chief Scientific Officer (Age 64)
- Mr. Christopher J. Morl, Chief Bus. Officer (Age 60)
- Mr. Thomas Patrick Kelly, Chief Financial Officer (Age 48)
- Dr. Stephen B. Ruddy, Chief Technical Officer
When did Deciphera Pharmaceuticals IPO?
(DCPH) raised $101 million in an initial public offering on Thursday, September 28th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Nomura were co-managers.
How do I buy shares of Deciphera Pharmaceuticals?
Shares of DCPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Deciphera Pharmaceuticals' stock price today?
One share of DCPH stock can currently be purchased for approximately $23.67.
How big of a company is Deciphera Pharmaceuticals?
Deciphera Pharmaceuticals has a market capitalization of $903.96 million. The company earns $-99,850,000.00 in net income (profit) each year or ($2.82) on an earnings per share basis.
What is Deciphera Pharmaceuticals' official website?
How can I contact Deciphera Pharmaceuticals?
Deciphera Pharmaceuticals' mailing address is 500 Totten Pond Road, Waltham MA, 02451. The company can be reached via phone at 781-209-6400 or via email at [email protected]
MarketBeat Community Rating for Deciphera Pharmaceuticals (NASDAQ DCPH)
MarketBeat's community ratings are surveys of what our community members think about Deciphera Pharmaceuticals and other stocks. Vote "Outperform" if you believe DCPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DCPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
